2-methyl-2-(3-methyl-4-nitro-1H-pyrazol-1-yl)propanamide | 1374829-43-2

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 2-methyl-2-(3-methyl-4-nitro-1H-pyrazol-1-yl)propanamide
• 英文别名: 2-methyl-2-(3-methyl-4-nitropyrazol-1-yl)propanamide
• CAS: 1374829-43-2
• 化学式: C₈H₁₂N₄O₃
• 分子量: 212.208
• InChiKey: WJDDVKQDZUPKRU-UHFFFAOYSA-N

物化性质

• 沸点：
  408.8±35.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-2-(3-methyl-4-nitro-1H-pyrazol-1-yl)propanamide 在 lithium hexamethyldisilazane 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 2-(5-chloro-3-methyl-4-nitro-1H-pyrazol-1-yl)-2-methylpropionitrile
  参考文献：
  名称：

  [EN] AROMATIC HETEROCYCLIC COMPOUND AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  [FR] COMPOSÉ HÉTÉROCYCLIQUE AROMATIQUE ET INTERMÉDIAIRE, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE
  [ZH] 一种芳杂环类化合物及其中间体、药物组合物和用途

  摘要：

  本发明属于医药技术领域，涉及一类作为LRRK2抑制剂的芳杂环化合物。本发明提供了一类结构新颖的化合物，具有如式(K)所示的结构，为LRRK2抑制剂类药物的发展提供了一个新的方向。体外酶及细胞活抑制活性研究显示，这些化合物都具有较强的抑制作用，可作为预防或治疗由LRRK2介导的疾病的前景化合物。

  公开号：

  WO2023222005A1
• 作为产物：
  描述：

  2-methyl-2-(3-methyl-4-nitro-1H-pyrazol-1-yl)propanoyl chloride 在 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 2-methyl-2-(3-methyl-4-nitro-1H-pyrazol-1-yl)propanamide
  参考文献：
  名称：

  Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

  摘要：

  Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is one of the most compelling targets for a potential disease-modifying Parkinson's disease therapy. Herein, we disclose structurally diverse small molecule inhibitors suitable for assessing the implications of sustained in vivo LARK2 inhibition. Using previously reported aminopyrazole 2 as a lead molecule, we were able to engineer structural modifications in the solvent-exposed region of the ATP-binding site that significantly improve human hepatocyte stability, rat free brain exposure, and CYP inhibition and induction liabilities. Disciplined application of established optimal CNS design parameters culminated in the rapid identification of GNE-0877 (11) and GNE-9605 (20) as highly potent and selective LRRK2 inhibitors. The demonstrated metabolic stability, brain penetration across multiple species, and selectivity of these inhibitors support their use in preclinical efficacy and safety studies.

  DOI：

  10.1021/jm401654j

文献信息

• [EN] COMPOUND, COMPOSITIONS, AND METHODS<br/>[FR] COMPOSÉS, COMPOSITIONS, ET PROCÉDÉS
  申请人：DENALI THERAPEUTICS INC

  公开号：WO2017087905A1

  公开（公告）日：2017-05-26

  Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  披露了具有LRRK2抑制剂活性的化合物。这些化合物具有公式(I)，包括立体异构体、互变异构体、药物可接受的盐和前药。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• [EN] PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS<br/>[FR] DÉRIVÉS DE PYRAZOLE AMINOPYRIMIDINE EN TANT QUE MODULATEURS DE LRRK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013164321A1

  公开（公告）日：2013-11-07

  Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  Pyrazole化合物是LRRK2的调节剂，制备这些化合物的方法，以及利用这些化合物治疗与LRRK2受体相关的疾病的方法，如帕金森病。
• [EN] PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS<br/>[FR] DÉRIVÉS DE PYRAZOLE AMINOPYRIMIDINE EN TANT QUE MODULATEURS DU LRRK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012062783A1

  公开（公告）日：2012-05-18

  Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  化合物的结构式（I）或其药用盐，其中X，R1，R2，R3，R4和R5如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗与LRRK2受体相关的疾病，如帕金森病。
• [EN] HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] HÉTÉROARYLAMINOPYRIMIDINE AMIDES INHIBITEURS D'AUTOPHAGIE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：DECIPHERA PHARMACEUTICALS LLC

  公开号：WO2020231808A1

  公开（公告）日：2020-11-19

  Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers. (I)

  本文描述了抑制自噬的化合物及其在治疗癌症等疾病中的应用。
• [EN] AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE L'AUTOPHAGIE À BASE D'AMIDE D'AMINOPYRIMIDINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：DECIPHERA PHARMACEUTICALS LLC

  公开号：WO2020257180A1

  公开（公告）日：2020-12-24

  Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

  本文描述了一些抑制自噬的化合物及其在治疗癌症等疾病中的应用。